Yes, I'm trying to focus more on Gilead right now, we'll see, are you clear now? how are you doing?
Nick
mallani said
May 7, 2013
Hi Nick,
AbbVie will not accept anyone who has had a previous DAA for their trials. As DEB025 is not a DAA I can understand why you are not impressed by their attitude. One of our Forum members had failed Incivek Rx, but was accepted onto a Gilead/BMS trial, and achieved SVR. AbbVie are probably worried about resistant mutations affecting ABT-267, their NS-5b polymerase inhibitor. They did 2 Phase2 trials using this drug with Riba. but did not publish results. This makes me think there were high levels of resistant mutations. Also, the Phase 2 trials using all 3 of their drugs, showed much better SVR rates for Geno1b (compared to 1a). Again, this suggests that resistant mutations were a problem. Have you tried to get on a Gilead Trial ? Cheers
Roadwarrior said
May 6, 2013
Hi Malcolm
Thanks for you reply, you confirmed what I know, that there a litlle or no resistance problems regarding Alisporvir. Seemed to have backed into a corner thro getting involved with that trial. As you are probably aware the FDA stopped it on danger grounds. As you say Abbvie may be being over cautious.
How are you doing?
Nick
mallani said
May 5, 2013
Hi Nicolas,
You asked the same question in your previous post of 3rd May. Bills and I responded to your question, but you did not reply.
AbbVie are concerned about resistant mutations. DEB025 (Alisporvir) acts on the hepatocyte cytoplasm, and indirectly on the HCV site NS-5a. If you read the link I have posted (below), you will see that there is a 'lack of cross-resistance between DEB025 and DAA's of other classes', and that 'there is a high genetic barrier to resistance to DEB025'. AbbVie are obviously being very cautious.
has anyone any information regarding drug resistance issues surrounding Alisporvir debio025 cyclophin inhibitor, Abbvie have told me they cannot consider me for their interferon free studies.
Hi Malcolm
Yes, I'm trying to focus more on Gilead right now, we'll see, are you clear now? how are you doing?
Nick
Hi Nick,
AbbVie will not accept anyone who has had a previous DAA for their trials. As DEB025 is not a DAA I can understand why you are not impressed by their attitude. One of our Forum members had failed Incivek Rx, but was accepted onto a Gilead/BMS trial, and achieved SVR. AbbVie are probably worried about resistant mutations affecting ABT-267, their NS-5b polymerase inhibitor. They did 2 Phase2 trials using this drug with Riba. but did not publish results. This makes me think there were high levels of resistant mutations. Also, the Phase 2 trials using all 3 of their drugs, showed much better SVR rates for Geno1b (compared to 1a). Again, this suggests that resistant mutations were a problem. Have you tried to get on a Gilead Trial ? Cheers
Hi Malcolm
Thanks for you reply, you confirmed what I know, that there a litlle or no resistance problems regarding Alisporvir. Seemed to have backed into a corner thro getting involved with that trial. As you are probably aware the FDA stopped it on danger grounds. As you say Abbvie may be being over cautious.
How are you doing?
Nick
Hi Nicolas,
You asked the same question in your previous post of 3rd May. Bills and I responded to your question, but you did not reply.
AbbVie are concerned about resistant mutations. DEB025 (Alisporvir) acts on the hepatocyte cytoplasm, and indirectly on the HCV site NS-5a. If you read the link I have posted (below), you will see that there is a 'lack of cross-resistance between DEB025 and DAA's of other classes', and that 'there is a high genetic barrier to resistance to DEB025'. AbbVie are obviously being very cautious.
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0013687
Hi everyone
has anyone any information regarding drug resistance issues surrounding Alisporvir debio025 cyclophin inhibitor, Abbvie have told me they cannot consider me for their interferon free studies.
good energy to all
Nick